Thailand information guide for expats
Retatrutide in Thailand: What Expats Need to Know
Retatrutide is an investigational medicine being studied in clinical trials. This guide explains what Lilly has published about its research, current approval status and safety questions for people living in or visiting Thailand.
What is retatrutide?
Eli Lilly describes retatrutide as an investigational triple hormone receptor agonist. It is designed to activate receptors for GIP, GLP-1 and glucagon. Lilly is evaluating it in clinical trials; it is not an approved treatment for general use.
Is retatrutide approved in Thailand?
In information updated in September 2026, Lilly says retatrutide has not been approved by any regulatory agency and is not available for public use. Lilly says it is being studied in clinical trials.
This page is not a legal assessment of Thai regulations. For questions about local requirements, check current information from Thai authorities and speak with a qualified healthcare professional.
What have clinical trials found?
Lilly reported results from TRIUMPH-2, an 80-week Phase 3 trial involving participants with obesity or overweight and type 2 diabetes. In the 12 mg group, the average weight reduction reported at 80 weeks was 20.8%.
This figure describes a specific trial group and study conditions. It does not predict an individual’s results, and it does not mean retatrutide is an approved treatment. The trial also reported adverse events; research into safety and efficacy is ongoing.
Safety and products sold online
A product label or online claim cannot confirm what a product contains or whether it is safe for human use. Lilly warns that products claiming to be retatrutide outside its clinical trials may contain unknown or incorrect ingredients, contaminants or impurities.
Frequently asked questions
Can a clinic in Thailand provide retatrutide?
This guide cannot verify or recommend a clinic or seller. A claim that a product is available does not establish its regulatory status or quality. Check current information with Thai authorities and a qualified healthcare professional.
Is retatrutide the same as tirzepatide or semaglutide?
No. They are different medicines. Retatrutide is still being studied, so comparisons should distinguish clinical-trial findings from approved treatments.
Is “GLP-3” the official name for retatrutide?
No. Lilly describes “GLP-3” as an informal and scientifically inaccurate term. “Triple agonist” is a more accurate description.
Is this page medical advice?
No. This page is for general educational purposes and is not a substitute for advice from a qualified healthcare professional.
Sources
- Eli Lilly: What to know about retatrutide
- Eli Lilly: TRIUMPH-2 Phase 3 results